Scandion Oncology A/S (SCOL.ST)
SEK 0.01
(-5.04%)
SEK 0.01
(-5.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -45.35 Million DKK | 43.42% |
| 2022 | -80.16 Million DKK | -44.79% |
| 2021 | -55.36 Million DKK | -141.9% |
| 2020 | -22.88 Million DKK | -48.7% |
| 2019 | -15.39 Million DKK | -54.93% |
| 2018 | -9.93 Million DKK | -464.62% |
| 2017 | -1.75 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.1 Million DKK | 9.46% |
| 2024 Q2 | -9.35 Million DKK | 7.34% |
| 2023 Q4 | -11.15 Million DKK | -2.25% |
| 2023 Q2 | -11.31 Million DKK | 5.48% |
| 2023 FY | -45.8 Million DKK | 42.86% |
| 2023 Q1 | -11.97 Million DKK | 31.3% |
| 2023 Q3 | -10.91 Million DKK | 3.6% |
| 2022 Q2 | -24.84 Million DKK | -52.28% |
| 2022 Q4 | -17.42 Million DKK | 25.14% |
| 2022 FY | -80.16 Million DKK | -44.79% |
| 2022 Q1 | -16.31 Million DKK | -2.15% |
| 2022 Q3 | -23.28 Million DKK | 6.27% |
| 2021 Q1 | -9.9 Million DKK | -7.9% |
| 2021 FY | -55.36 Million DKK | -141.9% |
| 2021 Q4 | -15.96 Million DKK | -4.48% |
| 2021 Q3 | -15.28 Million DKK | 0.09% |
| 2021 Q2 | -15.29 Million DKK | -54.44% |
| 2020 Q2 | -4.74 Million DKK | -17.65% |
| 2020 Q1 | -4.03 Million DKK | -246.11% |
| 2020 Q4 | -9.17 Million DKK | -87.24% |
| 2020 FY | -22.88 Million DKK | -48.7% |
| 2020 Q3 | -4.9 Million DKK | -3.3% |
| 2019 Q4 | -1.16 Million DKK | 83.42% |
| 2019 FY | -15.39 Million DKK | -54.93% |
| 2019 Q3 | -7.03 Million DKK | -44.92% |
| 2019 Q2 | -4.85 Million DKK | -106.87% |
| 2019 Q1 | -2.34 Million DKK | 57.95% |
| 2018 Q2 | -2.36 Million DKK | -240.42% |
| 2018 Q4 | -5.57 Million DKK | -330.38% |
| 2018 FY | -9.93 Million DKK | -464.62% |
| 2018 Q1 | -695.13 Thousand DKK | -10.01% |
| 2018 Q3 | -1.29 Million DKK | 45.24% |
| 2017 Q3 | -541.13 Thousand DKK | 0.0% |
| 2017 FY | -1.75 Million DKK | 0.0% |
| 2017 Q4 | -631.87 Thousand DKK | -16.77% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcouSort AB (publ) | -17.48 Million SEK | -159.376% |
| Active Biotech AB (publ) | -46.48 Million SEK | 2.424% |
| Alzinova AB (publ) | -16.52 Million SEK | -174.525% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -209.816% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 81.783% |
| BioArctic AB (publ) | 252.64 Million SEK | 117.953% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 88.2% |
| Camurus AB (publ) | 532.35 Million SEK | 108.52% |
| Cantargia AB (publ) | -290.01 Million SEK | 84.361% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -125.22% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 69.054% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 60.584% |
| Kancera AB (publ) | -65.04 Million SEK | 30.265% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1194.066% |
| LIDDS AB (publ) | -40.67 Million SEK | -11.513% |
| Lipum AB (publ) | -37.25 Million SEK | -21.751% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -266.64% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 351.857% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -176.55% |
| NextCell Pharma AB | -43.17 Million SEK | -5.061% |
| Saniona AB (publ) | -81.06 Million SEK | 44.049% |
| Simris Alg AB (publ) | -36.63 Million SEK | -23.808% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 85.892% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -165.303% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 85.389% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 74.908% |
| Amniotics AB (publ) | -29.07 Million SEK | -56.011% |
| CombiGene AB (publ) | -36.3 Million SEK | -24.933% |
| Genovis AB (publ.) | 54.22 Million SEK | 183.647% |
| Mendus AB (publ) | -100.65 Million SEK | 54.936% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -8.814% |
| OncoZenge AB (publ) | -15.9 Million SEK | -185.228% |
| Xintela AB (publ) | -57.23 Million SEK | 20.757% |
| Ziccum AB (publ) | -21.56 Million SEK | -110.376% |
| Intervacc AB (publ) | -93.57 Million SEK | 51.531% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -5267.692% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -192.399% |
| Corline Biomedical AB | -1.78 Million SEK | -2436.745% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 74.908% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 18.153% |
| Aptahem AB (publ) | -10.1 Million SEK | -348.868% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 66.307% |
| Fluicell AB (publ) | -26.87 Million SEK | -68.745% |
| Biovica International AB (publ) | -126.07 Million SEK | 64.023% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -6.71% |
| Abliva AB (publ) | -96.54 Million SEK | 53.021% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 86.035% |
| 2cureX AB (publ) | -36.36 Million SEK | -24.734% |
| I-Tech AB | 24.43 Million SEK | 285.623% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.248% |
| Cyxone AB (publ) | -21.66 Million SEK | -109.395% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 57.196% |
| Biosergen AB | -27.26 Million SEK | -66.356% |
| Nanologica AB (publ) | -69.96 Million SEK | 35.17% |
| SynAct Pharma AB | -224.49 Million SEK | 79.796% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -2.673% |
| BioInvent International AB (publ) | -369.94 Million SEK | 87.739% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -89.348% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 82.104% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -609.451% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 59.106% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -292.158% |